Phase II study of the oral HIF-2 alpha inhibitor MK-6482 for Von Hippel-Lindau disease-associated renal cell carcinoma.

Jonasch, E; Donskov, F; Iliopoulos, O; Rathmell, WK; Narayan, V; Maughan, BL; Oudard, S; Else, T; Maranchie, JK; Welsh, SJ; Thamake, S; Park, EK; Zojwalla, NJ; Perini, RF; Linehan, WM; Srinivasan, R

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (15):

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索